Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer - Wikidata - wikimedia - TriplyDB

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

http://www.wikidata.org/entity/Q35469572

about

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70 Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment Expression-based Pathway Signature Analysis (EPSA): mining publicly available microarray data for insight into human disease.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.An AlphaScreen-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction.Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity.Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells Heat shock protein 90 inhibition in lung cancer.A novel class of small molecule inhibitors of Hsp90.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90 Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation.VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.HER2 breast cancer therapies: a review The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

P2860

Q21195221-D8F41CE7-BDC3-4923-B9AC-DD3A8506D112 Q24657439-7D6CEA3B-FD47-44A4-956B-CB611A622A3B Q27022514-C06F72D7-A273-44FB-B83D-4A1CCA9D66E7 Q28271726-A16BF02F-0A27-4060-8B52-E3B24C40F439 Q28472376-EB89C218-1533-48DF-9B91-47A13FDAC484 Q28477468-11F2365F-838F-4A70-97A8-5AC35B4CB193 Q33378247-35EC85D5-13BB-4BE0-8C47-FBA4CBC7236B Q33387877-6E10C688-71AD-455D-80BD-DA330B907119 Q33388351-55C5667C-5482-46C1-B573-88E3016DA467 Q33390600-C40B9F85-1C93-4C9B-ABEC-AF410AF995F0 Q33397124-55E8F66E-87F2-430E-8DE6-519C4CF2207F Q33408481-67049146-2082-45F7-BB50-EABDC77ED2ED Q33440318-2B6BA2EC-344D-493A-9187-014AF87F03EC Q33584583-A00AA992-26E5-4438-8ECA-7A45384EEB69 Q33998634-A5A879D8-179F-476D-8394-A56C9458FD40 Q34162151-79607942-AF1E-4B58-AFBB-495AA5378608 Q34374079-DF528650-F0CF-4F5C-93C1-24D56684414C Q34616517-F1D38F87-CA70-41A1-9A7B-7342FF18C800 Q35169884-7136E2DA-316C-4778-84F8-842B5497CF0E Q35194754-2ED430F8-1635-49F7-8D5F-46B48408A589 Q35469447-B0D3287A-21A6-455D-BD19-95174097AC26 Q35691439-D130E5AB-1F31-4E72-882D-DBACC971404B Q35754391-6DB0A90F-A324-44D4-86AD-6E7C63B2376A Q35762499-A8AD1C33-06B5-4873-A6FF-1EA3A090D1C1 Q35764444-618B05BA-1A72-4279-9DB1-0B2A618E676D Q36162690-B5324B0A-439C-4540-B8AC-1DB02BC6E301 Q36310262-C4C7F636-779F-4C8E-B792-F0EAB51923B4 Q36312850-7C082658-372D-4458-8CA5-B5CDE9E1530D Q36316817-FC3464B3-A221-45F3-98BB-5CE313C5FCE7 Q36325610-D638D9A4-ED7D-4C2E-9FF8-337055DF214A Q36501393-0A75CE89-AD86-4AF7-B3C4-FECAD91F573F Q36976738-DB63BC84-E4DE-42FF-963C-AB328A165C8A Q37068863-85136379-D8CC-4B55-BB70-B3958093DF91 Q37072437-8ABE220F-851B-49F6-8EF9-81410444084D Q37075370-E81B2F58-D773-4B30-8B3C-2E85512A945F Q37092020-FA898287-E8AC-4463-B6A9-93B3FD6273C0 Q37130217-6DA994D6-0AD2-48C7-912D-7AED9E135922 Q37215989-389BBFF0-88DE-41DA-B1D2-EAD8F38469D8 Q37303196-864D94E9-A0F2-43F5-B54A-85965E322B70 Q37333665-C51FD657-F52D-4D7F-BC66-FC1EE10A188D

P2860

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

http://www.wikidata.org/entity/Q35469572

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@ast

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@en

type

label

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@ast

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@en

prefLabel

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@ast

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@en

P1433

Q35469572-517FC6F1-CA17-4DEC-BD0A-AE5440272F28

P1476

Q35469572-D0456429-855E-4B9F-8D1F-74CD1AF06649

P2093

Q35469572-0D47813D-68AA-4613-8556-A0959A294003

Q35469572-1DE33847-05F6-41E3-84F8-3C8C6324747E

Q35469572-2FA3A417-C17D-422E-83B4-0A0ABB6C0A01

Q35469572-35183CC0-D20F-4E6F-83CF-2AB8ABFD8946

Q35469572-4E8162C1-245E-48CD-82C5-B616526955A2

Q35469572-54A60121-DECC-4E36-9FFD-BDD61B3AF64E

Q35469572-558264C0-31C8-438E-8E00-068A616BACA2

Q35469572-64352F25-84A0-4175-9CD4-B823906F0BFF

Q35469572-7A92A9F4-E0D7-429C-ACC7-FB7D0D2DAA43

Q35469572-834425AC-C879-49B0-AFFE-BC711311C620

P2860

Q35469572-04EC20EB-F2A5-482E-A1F2-6DF76779CEB0

Q35469572-0FB39FDA-1AA2-458E-A144-951264BFBE58

Q35469572-24B31F8C-CF71-477E-ADC3-EAF432C14527

Q35469572-366CDF80-CBDF-41A7-993A-6B1E0928351D

Q35469572-3A624E88-A3B4-40F5-88BD-8806CB3ADBEC

Q35469572-3DE0B696-3ADE-4A96-A442-1AA57013C34B

Q35469572-3E6123D4-2708-41B9-BC88-D03EEB3D78B0

Q35469572-3F93942B-D9F9-4C21-A4A1-465EA141DC95

Q35469572-48056AC4-CF67-4082-82D2-624AE7DA6E8F

Q35469572-4818A277-C17C-4039-BD07-E0DFD39322F8

P304

Q35469572-8E002E31-EEB5-42E4-B594-99FFFFBFE040

P31

Q35469572-E42A193C-395C-4F26-B6D0-0C5285ED4852

P356

Q35469572-575612F3-7626-4D03-BC54-9E5C1AE00CBF

P407

Q35469572-BB5F5458-4EEC-48F1-BADA-14D393B95FF2

P433

Q35469572-0C471FB8-60ED-412A-ADDC-F80F413D8050

P478

Q35469572-269D015E-E64B-4CF6-A6E1-4D685D164F7A

P577

Q35469572-CE0F4254-370C-434B-BF68-62A544AA890B

P698

Q35469572-25B8F2FF-6E3F-460E-A2D1-5B5B65059236

P921

Q35469572-BF86BA4B-1B07-4BC4-A866-B9B9B97EF567

P932

Q35469572-67B4D321-35A3-483F-B3DB-452AEA2BFD51

P356

1078-0432.CCR-06-1863

P1433

Clinical Cancer Research

P1476

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

@en

P2093

Anthony DeLaCruz

http://www.w3.org/2001/XMLSchema#string

Catherine Kopil

http://www.w3.org/2001/XMLSchema#string

David B Solit

http://www.w3.org/2001/XMLSchema#string

Glenn Heller

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Lawrence Schwartz

http://www.w3.org/2001/XMLSchema#string

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Michael J Morris

http://www.w3.org/2001/XMLSchema#string

Neal Rosen

http://www.w3.org/2001/XMLSchema#string

Rachel Sikorski

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo.

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

P304

1775-1782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-06-1863

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17363532

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3203693

http://www.w3.org/2001/XMLSchema#string